(MedPage Today) — SAN FRANCISCO — Perioperative treatment with enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) significantly improved survival compared with standard neoadjuvant chemotherapy in patients with muscle-invasive bladder…
Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/120087
Author :
Publish date : 2026-02-27 20:11:00
Copyright for syndicated content belongs to the linked Source.










